Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

1. García-Gutiérrez, V.
2. Puerta, J.M.
3. Maestro, B.
4. Casado Montero, L.F.
5. Muriel, A.
6. Molina Hurtado, J.R.
7. Perez-Encinas, M.
8. Moreno Romero, M.V.
9. Suñol, P.B.
10. Sola Garcia, R.
11. De Paz, R.
12. Ramirez Sanchez, M.J.
13. Osorio, S.
14. Mata Vazquez, M.I.
15. Martinez López, J.
16. Sastre, J.L.
17. Portero, M.D.L.A.
18. Bautista, G.
19. Duran Nieto, M.S.
20. Giraldo, P.
21. Jimenez Jambrina, M.
22. Burgaleta, C.
23. Ruiz Aredondo, J.
24. Peñarrubia, M.J.
25. Requena, M.J.
26. Fernández Valle, M.D.C.
27. Calle, C.
28. Paz Coll, A.
29. Hernández-Rivas, J.Á.
30. Franco Osorio, R.
31. Cano, P.
32. Tallón Pérez, D.
33. Fernández de la Mata, M.
34. Garrido, P.L.
35. Steegmann, J.L.
36. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1002/AJH.23816 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus